Form 8-K

8-K — HALOZYME THERAPEUTICS, INC.

Accession: 0001159036-26-000053

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0001159036

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — halo-20260430.htm (Primary)

EX-99.1 (darrensnellgrovepressrelea.htm)

GRAPHIC (halo-20260430_g1.jpg)

GRAPHIC (image_0.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: halo-20260430.htm · Sequence: 1

halo-20260430

FALSE000115903600011590362026-04-302026-04-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________

FORM 8-K

_____________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 30, 2026

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

________________________

Commission File Number 001-32335

Delaware 88-0488686

(State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.)

12390 El Camino Real 92130

San Diego (Zip Code)

California

(Address of principal executive offices)

(858) 794-8889

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value HALO The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026. Since May 2025, Mr. Snellgrove (age 52) has served as Vice President, Investor Relations at Johnson & Johnson, a multinational pharmaceutical, biotechnology and medical technologies corporation (“J&J”). From August 2021 to May 2025, he served as the CFO of J&J’s Pharmaceutical sector. Previously he served in other finance leadership positions at J&J, including as CFO, VP Finance and Operations Pharmaceutical R&D from 2017 to August 2021, and as CFO, J&J Innovation from 2013 to 2017. Prior to 2013, Mr. Snellgrove served in other positions of increasing responsibility at J&J, including serving as CFO, Janssen Alzheimer Immunotherapy. Mr. Snellgrove holds a B.A. Honors Degree in Economics and Philosophy from Southampton University, England and an M.B.A. from Villanova University. Effective as of June 8, 2026, David Ramsay, the Company’s current Interim CFO, will assume an advisory role with the Company to assist during a brief transition period.

In his role as CFO, Mr. Snellgrove will be paid an annual salary of $670,000 and he will be eligible to participate in the Company’s executive officer incentive plans, with a bonus target equal to 50% of his base salary, which will be prorated in 2026. Beginning in 2027, Mr. Snellgrove will be eligible to receive long-term incentive awards in accordance with the Compensation Committee’s equity award grant practices for the Company’s executive officers. Mr. Snellgrove’s 2027 long-term incentive award will have a minimum total grant date value of $4,000,000.

Upon joining the Company, Mr. Snellgrove will receive equity awards with a total grant date value of $7,200,000. This includes $3,200,000 in restricted stock units (“RSUs”), which is intended to make Mr. Snellgrove whole for equity value forfeited in connection with his acceptance of employment at Halozyme following 27 years of service at J&J, and vests one-third on each of the first three anniversaries of the date of grant. It also includes $4,000,000 in stock options that will vest 25% after one year and then in equal monthly installments over the next three years in accordance with the Company’s standard equity award practices for the Company’s executive officers. The equity award will be granted under, and be subject to the terms and conditions of, the Company’s 2021 Stock Plan. As is customary and prevalent competitive practice when hiring an experienced executive of Mr. Snellgrove’s caliber, the Compensation Committee provided the make-whole equity grant in RSUs ($3.2 million), while the balance of his new-hire equity awards was provided in stock options, which will deliver no value to Mr. Snellgrove absent an increase in our share price following his start date, in line with the Company’s pay-for-performance philosophy.

Additionally, a sign-on cash bonus of $350,000 will be provided to Mr. Snellgrove upon joining the Company to make him whole for forgone cash compensation at his former employer. A prorated portion of the sign-on cash bonus is subject to repayment if, within 24 months of hire, Mr. Snellgrove voluntarily terminates his employment or is terminated for misconduct.

There are no family relationships between Mr. Snellgrove and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer. Mr. Snellgrove does not have a direct or indirect material interest in any transaction or arrangement in which the Company is a participant.

On April 30, 2026, the Company issued a press release announcing the appointment of Mr. Snellgrove as CFO. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

Exhibits

Exhibit No. Description

99.1

Press Release of Halozyme Therapeutics, Inc. dated April 30, 2026

104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc.

(Registrant)

Dated:

April 30, 2026

By:

/s/ Mark Snyder

Mark Snyder

Senior Vice President, General Counsel and Corporate Secretary

EX-99.1

Filename: darrensnellgrovepressrelea.htm · Sequence: 2

Document

Exhibit 99.1

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

SAN DIEGO, April 30, 2026 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today announced the appointment of Darren Snellgrove as Chief Financial Officer (CFO), effective June 8, 2026.

Mr. Snellgrove will be responsible for leading Halozyme’s financial operations and strategy, including capital allocation, corporate development and investor relations. Darren will report to Helen Torley, President and Chief Executive Officer.

“I am delighted to have a financial leader of Darren’s experience and caliber join Halozyme at this exciting time. He is a highly respected finance leader with deep experience and an expansive skillset, demonstrated by successful leadership across major portfolio investments and a strong, well-established record of investor engagement,” said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. “I look forward to having Darren join our leadership team and contribute to the acceleration of value creation for our shareholders.”

Mr. Snellgrove brings more than 30 years of exceptional financial leadership, strategic insight, and operational excellence across the biopharmaceutical and medtech sectors. Most recently, he led investor relations at Johnson & Johnson, a Fortune 50 healthcare company. In that role, he reshaped corporate messaging and investor engagement strategies, strengthened analyst and shareholder relationships, and supported strong market performance.

Previously, Mr. Snellgrove served as Chief Financial Officer of Johnson & Johnson’s Pharmaceuticals sector, where he provided global financial leadership for a business generating more than $50 billion in annual revenue. During his tenure, he delivered impressive financial results, leading large global teams across commercial operations, R&D, supply chain, and business development, and played a central role in major portfolio investments, restructuring initiatives, and business development transactions.

Earlier in his career, Mr. Snellgrove held CFO and senior finance leadership roles across pharmaceutical R&D, innovation, and M&A at Johnson & Johnson, as well as progressive finance roles at Centocor prior to its acquisition.

“I am thrilled to join Halozyme at such an important time in the Company’s evolution,” said Mr. Snellgrove. “Halozyme’s technology has dramatically improved the delivery of biologics for patients, and the company has built a broad technology portfolio with strong partners, durable

royalty streams, and significant long‑term opportunity. I look forward to working with Helen and the entire team to drive sustainable growth and value creation for shareholders.”

Mr. Snellgrove holds an MBA from Villanova University and a BA Honors degree from the University of Southampton in England.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio’s hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at‑home and healthcare‑provider settings. The addition of Surf Bio’s polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio’s technology complement ENHANZE® by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx and Vertex Pharmaceuticals.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding Halozyme’s future performance, durability of revenues, shareholder value creation and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues, expenditures, costs and growth. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

Contacts:

Tram Bui

VP, Investor Relations and Corporate Communications

609-333-7668

tbui@halozyme.com

Sydney Charlton

Teneo

917-972-8407

sydney.charlton@teneo.com

GRAPHIC

Filename: halo-20260430_g1.jpg · Sequence: 6

Binary file (15840 bytes)

Download halo-20260430_g1.jpg

GRAPHIC

Filename: image_0.jpg · Sequence: 7

Binary file (17552 bytes)

Download image_0.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover Page

Apr. 30, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Apr. 30, 2026

Entity Registrant Name

HALOZYME THERAPEUTICS, INC.

Entity File Number

001-32335

Entity Incorporation, State or Country Code

Entity Tax Identification Number

88-0488686

Entity Address, Address Line One

12390 El Camino Real

Entity Address, City or Town

San Diego

Entity Address, State or Province

Entity Address, Postal Zip Code

92130

City Area Code

858

Local Phone Number

794-8889

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value

Trading Symbol

HALO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Amendment Flag

false

Entity Central Index Key

0001159036

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration